{"id":251885,"date":"2025-01-23T00:00:00","date_gmt":"2025-01-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidon0219-biopharma-waldenstrom-macroglobulinemia-epidemiology\/"},"modified":"2026-03-31T10:27:16","modified_gmt":"2026-03-31T10:27:16","slug":"epidon0219-biopharma-waldenstrom-macroglobulinemia-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0219-biopharma-waldenstrom-macroglobulinemia-epidemiology-mature-markets\/","title":{"rendered":"Waldenstrom Macroglobulinemia &#8211; Epidemiology &#8211; Mature markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of Waldenstrom macroglobulinemia (<abbr title=\"Waldenstr\u00f6m macroglobulinemia\">WM<\/abbr>) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the diagnosed incidence and diagnosed prevalence of <abbr title=\"Waldenstr\u00f6m macroglobulinemia\">WM<\/abbr> and non-<abbr title=\"Waldenstr\u00f6m macroglobulinemia\">WM<\/abbr>, non-gamma heavy chain disease (<abbr title=\"Gamma heavy-chain disease\">gHCD<\/abbr>) <abbr title=\"lymphoplasmacytic lymphoma\">LPL<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"Waldenstr\u00f6m macroglobulinemia\">WM<\/abbr> and non-<abbr title=\"Waldenstr\u00f6m macroglobulinemia\">WM<\/abbr>, non-<abbr title=\"Gamma heavy-chain disease\">gHCD<\/abbr> <abbr title=\"lymphoplasmacytic lymphoma\">LPL<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with <abbr title=\"Waldenstr\u00f6m macroglobulinemia\">WM<\/abbr> and non-<abbr title=\"Waldenstr\u00f6m macroglobulinemia\">WM<\/abbr>, non-<abbr title=\"Gamma heavy-chain disease\">gHCD<\/abbr> <abbr title=\"lymphoplasmacytic lymphoma\">LPL<\/abbr> per year?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"Waldenstr\u00f6m macroglobulinemia\">WM<\/abbr> and non-<abbr title=\"Waldenstr\u00f6m macroglobulinemia\">WM<\/abbr>, non-<abbr title=\"Gamma heavy-chain disease\">gHCD<\/abbr> <abbr title=\"lymphoplasmacytic lymphoma\">LPL<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr title=\"multiple sclerosis\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least ten years of forecast data for the following <abbr title=\"Waldenstr\u00f6m macroglobulinemia\">WM<\/abbr> and non-<abbr title=\"Waldenstr\u00f6m macroglobulinemia\">WM<\/abbr>, non-<abbr title=\"Gamma heavy-chain disease\">gHCD<\/abbr> <abbr title=\"lymphoplasmacytic lymphoma\">LPL<\/abbr>. subpopulations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases of <abbr title=\"Waldenstr\u00f6m macroglobulinemia\">WM<\/abbr><\/li>\n<li>Diagnosed incident cases of non-<abbr title=\"Waldenstr\u00f6m macroglobulinemia\">WM<\/abbr>, non-<abbr title=\"Gamma heavy-chain disease\">gHCD<\/abbr> <abbr title=\"lymphoplasmacytic lymphoma\">LPL<\/abbr><\/li>\n<li>Diagnosed incident cases of <abbr title=\"Waldenstr\u00f6m macroglobulinemia\">WM<\/abbr> based on symptom status<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"Waldenstr\u00f6m macroglobulinemia\">WM<\/abbr><\/li>\n<li>Diagnosed prevalent cases of non-<abbr title=\"Waldenstr\u00f6m macroglobulinemia\">WM<\/abbr>, non-<abbr title=\"Gamma heavy-chain disease\">gHCD<\/abbr> <abbr title=\"lymphoplasmacytic lymphoma\">LPL<\/abbr><\/li>\n<li>Diagnosed drug-treatable cases of <abbr title=\"Waldenstr\u00f6m macroglobulinemia\">WM<\/abbr><\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251885","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematological-malignancies","biopharma-therapy-areas-hematology","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251885\/revisions"}],"predecessor-version":[{"id":443097,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251885\/revisions\/443097"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}